332 results about "CD44" patented technology

A source of multipotent amniotic fluid / fetal stem cells (MAFSCs) is disclosed. MAFSC are of fetal origin and have a normal diploid karyotype. These cells are characterized by the following cell surface markers: SSEA3, SSEA4, Tra-1-60, Tra-1-81, Tra-2-54, HLA class I, CD13, CD44, CD49b, CD105 and are distinguished by the absence of the antigen markers CD34, CD45, and HLA Class II, but are distinguished from mouse embryonic stem cells in that these cells do not express the cell surface marker SSEA1. MAFSC express the stem cell transcription factor Oct-4. MAFSC cells can be propagated for an indefinite period of time in continuous culture in an undifferentiated state. The MAFSCs have the ability to differentiate in culture in a regulated manner, into three or more subphenotypes. Cells can then be differentiated into endodermal, mesodermal and ectodermal derived tissues in vitro and in vivo. A method for isolating, identifying, expanding and differentiating MAFSCs is disclosed.

It is intended to provide a method whereby a plural number of antibodies against cell surface antigens are quickly classified and to provide a method whereby antigens of the thus classified antibodies are quickly identified. Further, it is intended to provide a method of promoting the utilization of the useful data obtained by the above methods. Furthermore, it is intended to provide an antibody which is effective in treating or diagnosing cancer. Namely, a method of classifying antibodies which comprises: (1) the step of preparing a plural number of antibodies respectively recognizing cell surface antigens; (2) the step of bringing each of these antibodies into contact with a cell of the same species; (3) the step of analyzing each of the cells having been treated in the step (2) by flow cytometry and thus obtaining data indicating the reactivity of each antibody with its cell surface antigen; and (4) the step of comparing the thus obtained data and classifying the individual antibodies depending on the similarity. A method of identifying antigens which further comprises: (5) the step of selecting one to several antibodies from each antibody group formed in the step (4) and identifying antigens thereof; and (6) on the assumption that antigens of the antibodies belonging to a single antibody group are the same or highly related to one another, making relations between the antigens having been identified in the step (5) and the antibody groups to thereby identify the antigens. An antibody against HER1, an antibody against HER2, an antibody against CD46, an antibody against ITGA3, an antibody against ICAM1, an antibody against ALCAM, an antibody against CD147, an antibody against C1qR, an antibody against CD44, an antibody against CD73, an antibody against EpCAM and an antibody against HGFR, each obtained by using the above methods.

The invention relates to novel conjugates of CD44 antibodies with cytotoxic compounds, pharmaceutical compositions comprising such compounds, and their use in tumor therapy.

Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.

Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.

Pharmaceutical compositions and methods for treating cancer using CD44 antagonists are disclosed. In certain aspects, these pharmaceutical compositions and methods include treating a mammal having a cancer, such as glioma, colon cancer, breast cancer, prostate cancer, ovarian cancer, lung cancer, renal cell carcinoma, gastric cancer, esophageal cancer, head cancer, neck cancer, pancreatic cancer, or melanoma, with a CD44 fusion protein. These CD44 fusion proteins include CD44-Fc fusions and can be used to detect hyaluronan.

The invention relates to a hyaluronic-acid-based double-targeting nano-composite medicament and a preparation method thereof. Hydrophobic group ursodeoxycholic acid is included in a hyaluronic acid nano-polymer structure and can form an amphipathic polymer and automatically generate micelles in an aqueous solution, and polyethylene glycol can be introduced into the micelles to improve the dispersity and stability of a composite. An anti-tumor medicament can enter a nano-carrier through electrostatic adsorption or physical inclusion to generate a nano-medicament composite, wherein the nano-medicament composite is selectively concentrated in a tumor cell under an active targeting effect of hyaluronic acid and a surface CD44 receptor of a tumor cell, and promotes a tumor tissue to absorb the nano medicament-carrying composite by using a passive osmotic accumulation effect (EPR) at the same time. After an anti-tumor medicament is wrapped by a modified hyaluronic acid polymer, the anti-tumor medicament has the advantages of improving the bioavailability of the medicament, improving the targeting property, reducing the toxic and side effects, prolonging the half-life period of the medicament, being stably stored and the like, so that the tumor targeting therapy efficiency is improved in many ways.

The invention provides a hyaluronic acid vitamin E derivative. According to the hyaluronic acid vitamin E derivative, biological material hyaluronic acid and vitamin E succinic acid ester are taken as raw materials to form micelles in a water medium. The provided micelles can be self-assembled in an aqueous solution to form a micelle drug delivery system, the carrying of non-water-soluble drugs is achieved, and then the drug targeting function is achieved. According to the hyaluronic acid vitamin E derivative, the natural macromolecule hyaluronic acid is taken as the raw material, the non-toxic effect, moisture preservation and excellent biocompatibility and biodegradability are achieved. The hydrophobic vitamin E succinic acid ester is connected to a hyaluronic acid main chain, and the hyaluronic acid vitamin E derivative is formed. A preparation method is reasonable in design and easy in method, the reaction is easy to conduct, and the obtained micelles are structured in form and small in particle size. The hyaluronic acid vitamin E micelles are excellent in biocompatibility, hydrophily and biodegradability, high in hydrophobic drug warping capacity and specific binding capacity with CD44 receptors and capable of serving as excellent targeted drug delivery carriers. The structure formula of the hyaluronic acid vitamin E derivative is shown (please see the structure formula in the instruction).

This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.

The invention relates to pH-triggering-to-release multilevel targeting polymer micelle in tumor cells and a preparation method of the multilevel targeting polymer micelle. The micelle is formed by self assembly of hydrophobic modified polysaccharide polymer with an endosome pH sensitive characteristic in a water medium. A hyaluronic acid-deoxycholate-histidine polymer is used as a carrier, and caner initiatively-targeting endosome pH sensitive polymer micelle is prepared by virtue of an ultrasonic method or a dialysis method to wrap an antitumor drug difficult to dissolve. By using the synergistic mechanism of EPR-mediated passive targeting, CD44 receptor initiative targeting and pH sensitive targeting strategies, the 'whole-course targeting' guidance is performed at four medicine delivery key steps, i.e., blood long circulation, tumor tissue accumulation, cell digestion and intracellular drug release, so that multilevel targeting drug delivery is realized, the intracellular drug concentration is effectively increased, and a novel carrier and a preparation strategy are provided for improving the antitumor effect of the difficultly-soluble antitumor drug.

This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.

The present invention is a method for inducing cytotoxic T cell having an antigen-specific cytotoxic activity, a method for maintaining the cell, a method for continuously culturing the cell or a method for expanding the cell, comprising the step of culturing a cytotoxic T cell in the presence of at least one substance selected from the group consisting of (A) a substance having a binding activity to CD44; (B) a substance capable of regulating a signal emitted by binding a CD44 ligand to CD44; (C) a substance capable of inhibiting binding of a growth factor to a growth factor receptor; (D) a substance capable of regulating a signal emitted by binding of a growth factor to a growth factor receptor; and (E) fibronectin, a fragment thereof or a mixture thereof.

The invention provides for isolated population of pulp marrow similar cells (DPMSCs) and methods for isolating and using these cells. The population of DPMSCs are highly homogenous for CD1O, CD29, CD13, CD44, CD49a, CD49d, CD59, CD73, CDw90, CD105, Oct-4 Isoform A and B, Nanog, Sox-2, and SSEA-4.

The invention relates to dual-targeting ursolic acid (UA) / siRNA loaded fluorescent mesoporous silica dioxide-hyaluronic acid and application. The technical scheme of the invention lies in that 1, fluorescently-labeled mesoporous silica dioxide nano particles are synthesized through the template method; 2, the surface of FMSN is subjected to amino modification through 3-aminopropyltriethoxysilane; 3, ursolic acid (UA) and siRNA are jointly loaded into porous channels of the nano particles; 4, hyaluronic acid is loaded into the outer surfaces of the nano material in a wrapping manner through electrostatic absorption, so as to obtain the dual-targeting ursolic acid (UA) / siRNA loaded fluorescent mesoporous silica dioxide-hyaluronic acid nano particles. According to the dual-targeting ursolic acid (UA) / siRNA loaded fluorescent mesoporous silica dioxide-hyaluronic acid and application, the prepared nano material is uniform in particle size distribution, and good in dispersibility, the stability of siRNA can be improved, and besides, siRNA can further specifically target tumor cell surface adhesion molecules like ICAM and CD44, therefore the anti-tumor effect of drugs can be greatly improved, and the toxic and side effect of the drugs can be further reduced.

A method of treating or preventing a gastrointestinal cancer by inhibiting expression of a CD44-SLC1A2 fusion gene or a functional variant thereof, or by inhibiting the activity of a fusion protein expressed by the CD44-SLC1A2 fusion gene or the functional variant thereof.

The invention relates to the technical field of medicines, and provides a docetaxel and sulforaphane loaded hyaluronic acid modified poly(lactic-co-glycolic acid) copolymer self-assembled nano-particle, a preparation method thereof and an application of the self-assembled nano-particle in preparing a medicine for treating breast cancer. The microscopic structure of the nano-particle comprises a hydrophobic PLGA (poly(lactic-co-glycolic acid)) core and a hydrophilic HA (hyaluronic acid) shell, wherein the PLGA core is used for wrapping a medicine DTX (docetaxel) or SFN (sulforaphane), and the hydrophilic shell HA can target a breast cancer stem cell highly expressing a CD44 receptor. In-vitro cytotoxicity tests indicate that the drug-loaded nano-particle can play a good role in resisting differentiation of mammary gland cells and breast cancer stem cells when compared with free medicines; in-vivo tumor inhibition experiments indicate that the drug-loaded medicine is more effective than free medicines and combined free medicines, and has a small systematic toxicity. The nano-particle can play a role in simultaneously performing target differentiating on mammary gland cells and breast cancer stem cells, and a new strategy is provided to treatment of breast cancer.

The invention provides a reagent for detecting a Notch signal path as well as a PCR (Polymerase Chain Reaction) detecting method and application thereof. The detecting reagent comprises PCR reaction primers for detecting an ADAM10 gene, an ADAM17 gene, an AES gene, a CBL gene, a CCND1gene, a CD44 gene, and the like, and primers of corresponding internal-reference regulatory genes GAPDH (Reduced Glyceraldehyde-Phosphate Dehydrogenase), ACTB (Beta-Actin) and B2M (Beta-2-Microglobulin). The invention provides the reagent for detecting core molecule changes of the NOTCH signal channel; by virtue of the detecting reagent, genes associated with the NOTCH channel can be quickly detected on transcriptional level by virtue of real-time fluorescent quantitative PCR; on this basis, core molecules and a mechanism of action of a tumor NOTCH signal channel are analyzed and researched, so that an NOTCH regulatory channel of tumor-associated medicaments is quickly and accurately found, and therefore, a powerful tool is provided for screening anti-tumor medicaments, discussing the mechanism of a novel targeted medicament, and the like.

The invention provides compositions and methods for characterizing breast cancer stem In particular, the invention provides for the identification of cells expressing Twist and CD44 that express little or virtually undetectable levels of CD24 (i.e. a Twist+ / CD44+ / CD24− / low cell sub-population). The presence of such cells in a breast cancer specimen identifies the breast cancer as having increased metastic potential. Such cancers are identified as requiring aggressive therapies. Accordingly, the invention provides biomarkers suitable for identifying, diagnosing, and monitoring treatment of a subject with breast cancer.

The invention feature methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal.

This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.

The invention provides a method for administering streptolysin O for treatment of various conditions including connective tissue disorders, reproductive fibroses and conditions mediated by the CD44 receptor. The invention also provides methods for protecting nerve cells from the effects of neurotoxic agents by the administration of streptolysin O.

The invention relates to an exosome system for achieving sustained release of a CD44 positive exosome based on binding effect of hyaluronic acid and a membrane protein CD44 and a construction method and an application thereof. The CD44 positive exosome effectively binds to materials constructed by hyaluronic acid, so as to realize long-term release of the exosome. The method provided by the invention can effectively solve the problem of short staying time of the exosome in a body and improve the therapeutic efficiency of the exosome.

The present invention provides a method for treating retinopathy of prematurity (ROP) and related retinopathic diseases. The method comprises administering to the retina of a mammal suffering from, or at risk of developing, retinopathy of prematurity or a related retinopathic disease an amount of cells from a vasculotrophic lineage negative hematopoietic stem cell population, effective to promote beneficial physiological revascularization of damaged areas of the retina and to ameliorate damage to the retina caused by the disease. Preferably, the mammal is a human patient. In one preferred embodiment, the lineage negative hematopoietic stem cell population is a lineage negative hematopoietic stem cell population comprising hematopoietic stem cells and endothelial progenitor cells (i.e., Lin− HSC). In another preferred embodiment, the lineage negative hematopoietic stem cell population is an isolated myeloid-like bone marrow (MLBM) cell population in which the majority of the cells are lineage negative and express CD44 antigen and CD11b antigen. As an alternative, for treatment of newborn infants, a lineage negative hematopoietic stem cell population can be isolated from umbilical cord vein blood.

The invention relates to a preparation method of a hyaluronic acid-targeted multifunctional branched polyethyleneimine drug carrier. The method includes: dropwise adding EDC (1-ethyl-3-(3-dimethylaminepropyl)carbodiimide) and NHS (N-hydroxysuccinimide) activated NH2-PEG-COOH into PEI (polyethyleneimine) solution, performing stirring for reacting, and performing freeze-drying after dialysis to obtain PEI-PEG (polyethyleneimine-polyethylene glycol); dropwise adding EDC and NHS activated HA (hyaluronic acid) into PEI-PEG solution, performing dialysis after stirring, and performing freeze-drying to obtain PEI-(PEG-HA); dropwise adding FI solution into PEI-(PEG-HA) aqueous solution, and performing stirring in the shade, dialysis and freeze-drying to obtain the carrier. The method is low in cost and simple, has mild conditions, is easy to operate and has a promising application prospect. The PEI-FI-(PEG-HA) carrying DOX serves as a nano drug controlled-release system having good drug controlled-release effect and having significant targeting effect and inhibitory effect for CD44 receptor expressed tumor cells.

A mesenchymal stem cell cryoprotectant is disclosed. Raw materials of the cryoprotectant includes, by volume, 65.5-75.4% of 1640 culture liquid, 9.8-10.1% of dimethyl sulfoxide, 9.8-11.2% of human albumin, 9.9-10.8% of hydroxyethyl starch and 0.5-1.5% of a fibroblast growth factor. The cryoprotectant is more suitable for cryopreservation of mesenchymal stem cells, the anchoring rate of the mesenchymal stem cells after resuscitation reaches 90% or above, dead cells are few, and the quantity of cells obtained after culturing for 7 days is 2*10<7> per flask, thus greatly increasing the quantity of cells. During cell phenotype detection, CD44<+> is 99% or above and CD105<+> is 99% or above.

The invention relates to a preparation method of a hyaluronic acid modified superparamagnetic iron oxide / gold composite nanoprobe. A NaBH4 reduction method is used for preparing PEI coated Au nano-particles; Fe3O4 / Au-PEI composite nanoparticles are synthetized in one step through a modified coprecipitation method; then HA is modified on the surface of the Fe3O4 / Au-PEI composite nanoparticles, so as to prepare a Fe3O4 / Au-HA composite nanoprobe. The preparation method provided by the invention is simple in process, mild in reaction conditions, and easy to operate; the prepared Fe3O4 / Au-HA composite nanoprobe has a relatively high relaxation rate, has an excellent X-ray damping capacity, is excellent in colloidal stability and biocompatibility, and has a targeting capability of a high expression cancer cell of a specific CD44 acceptor, and has a potential application value in the field of internal tumor targeted MR / CT bimodal imaging diagnosis.

The invention provides a self-assembly hyaluronic acid-indissolvable prodrug-coated active medicine-encapsulated liposome nano administration system and a preparation method thereof, which belong to the field of a medicinal preparation. The nano administration system comprises the following components: an active medicine, a hyaluronic acid-indissolvable prodrug and liposome. The self-assembly hyaluronic acid-indissolvable prodrug-coated active medicine-encapsulated liposome nano administration system having the nano preparation property can effectively and rapidly deliver the active medicine and the prodrug to tumor part through EPR effect, and reduces the drug amount in normal tissue; based on active targeting of the self-assembly hyaluronic acid-indissolvable prodrug-coated active medicine-encapsulated liposome nano administration system, after the active medicine and the prodrug arrive near to the tumor part, CD44 acceptor combination can be highly expressed through hyaluronic acid and tumor cells, the medicine is mediated into the cells, the drug amount in normal tissue is enhanced, and the antineoplastic capability of the medicine is obviously increased. The administration system is characterized in that two medicines having synergism are simultaneously delivered on a same carrier, has consistency of space and time, increases the tumour targeting, and increases the medicine curative effect.

Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.